Genelux Corporation

NasdaqCM GNLX

Genelux Corporation Market Capitalization on January 14, 2025: USD 82.55 M

Genelux Corporation Market Capitalization is USD 82.55 M on January 14, 2025, a -75.63% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Genelux Corporation 52-week high Market Capitalization is USD 356.35 M on January 17, 2024, which is 331.70% above the current Market Capitalization.
Genelux Corporation 52-week low Market Capitalization is USD 43.50 M on August 05, 2024, which is -47.30% below the current Market Capitalization.
Genelux Corporation average Market Capitalization for the last 52 weeks is USD 109.40 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: GNLX

Genelux Corporation

CEO	Mr. Thomas Zindrick J.D.
IPO Date	Jan. 26, 2023
Location	United States
Headquarters	2625 Townsgate Road
Employees	24
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Key trends

Past 5 years